MicroRNA-122 as a regulator and biomarker of liver disease. (PubMed, J Mol Med (Berl)) - Sep 19, 2026 - "Finally, we critically appraise the failed clinical translation of anti-miR-122 therapeutics (miravirsen, RG-101), highlighting viral resistance, safety liabilities, and the tumor-suppressor paradox that constrains inhibition-based strategies. Collectively, miR-122 emerges as a minimally invasive biomarker and a biologically informative, though therapeutically challenging, target in liver disease."
Biomarker • Journal • Review • Colorectal Cancer • Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cancer • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • AMPK • CCNG1 • MIR122 • STK11 • TLR4
|
|
Adam Przybylkowski; Ceren Eyileten; Dagmara Mirowska-Guzel; Jeff Palatini; Joanna Mucha; Sara Ahmadova; Zofia Wicik
|